Antibody that specifically binds to human CTLA4 and medicaments and kits comprising the same

Abstract

The present invention discloses an antibody that specifically binds to human CTLA4, comprising three complementarily-determining regions; the three complementarity-determining regions are respectively: CDR1 with an amino acid sequence as shown in SEQ ID NO: 1, CDR2 with an amino acid sequence as shown in SEQ ID NO: 2, and CDR3 with an amino acid sequence as shown in SEQ ID NO: 3. Also disclosed are medicaments and kits comprising the antibodies described above. The antibodies of the present invention exhibit, but are not limited to, the following properties: (1) high affinity and specificity with human CTLA4; (2) able to block the interaction of CTLA4 with CD86 or CD80; (3) able to specifically bind to CTLA4 overexpressing cells; (4) enhancing activation of PBMC and/or T cells; (5) inhibiting tumor growth.

Dependencies are inferred from the claim text.